At a glance
ClinicalIndex Comparison RecordN/ACompleted· 241 enrolled
Drug / intervention
Endeavor Zotarolimus-Eluting Coronary Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
In Brief
A clinical study evaluating Endeavor Zotarolimus-Eluting Coronary Stent for Coronary Artery Disease. Completed, enrolled 241 participants across 1 site.
Detailed Summary
The objective of this study is to verify the safety and efficacy of the Endeavor Zotarolimus-Eluting Coronary Stent System for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length ≤27 mm in native coronary arteries with reference vessels ≥ 2.25 mm to ≤ 2.75 mm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionMar 2012
Study CompletionSep 2013
TodayJul 2026
First PostedFeb 7, 2008
Enrollment StartJan 1, 2008
Primary CompletionMar 1, 2012
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 18.4 years ago
Interventions
Endeavor Zotarolimus-Eluting Coronary Stentdevice